SAB Biotherapeutics, Inc. - stock earnings
SABS Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q3 | -5.1 million USD | 1.3 million USD |
| 2023Q2 | -6.9 million USD | 85518 USD |
| 2023Q1 | -7.9 million USD | 2.2 million USD |
| 2022Q4 | -7.9 million USD | 2.2 million USD |
| 2022Q3 | -6.3 million USD | 3.6 million USD |
| 2022Q2 | -4.8 million USD | 6.4 million USD |
| 2022Q1 | 985863 USD | 11.8 million USD |
| 2021Q4 | -17.9 million USD | 60.9 million USD |
| 2021Q3 | -326106 USD | 14.7 million USD |
| 2021Q2 | -2.9 million USD | 17.6 million USD |
| 2021Q1 | 1.4 million USD | 16.9 million USD |
| 2020Q3 | 9.9 million USD | 17.5 million USD |
SABS Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -27.2 million USD | ? USD |
| 2022 | -18.7 million USD | 23.9 million USD |
| 2021 | -17.4 million USD | 60.9 million USD |
| 2020 | 20.1 million USD | 55.2 million USD |
| 2019 | -9.4 million USD | 3.4 million USD |
SABS
Price: $4.09
52 week price:
Earnings Per Share: -7.64 USD
P/E Ratio: -0.99
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 35000
Market Capitalization: 41.5 million